SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a - 16 OR 15d - 16 OF
THE SECURITIES EXCHANGE ACT OF 1934

For the month of ~~December,~~ ~~2006~~February, 2007

SkyePharma PLC

(Translation of registrant's name into English)

SkyePharma PLC, 105 Piccadilly, London W1J 7NJ England

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40F.

Form 20-F X Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No X

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- _______

For immediateImmediate release
                                                                                            28Release                                           20 DecemberFebruary 20062007


                                                                                     SkyePharma PLC ("the Company")

                                                                  Notification of Major InterestInterests in Shares

In  accordance  withLONDON, the  Companies  ActUK, 198520 February 2007 -- SkyePharma PLC (as  amendedNasdaq: SKYE; LSE: SKP)  the  Company  was  informed  on, 27  December  2006  that  Lehman  Brothershas
International  (Europe)  ("Lehman")received hadnotification decreased  theirfrom holdingLegal by& 27,615,141  sinceGeneral theirGroup lastPlc filingthat onit 18now December  2006.  Lehman's
revisedhas holdingan amountsinterest
in to 4827,699597,054887 SkyePharma Ordinary Shares of £0.10p eachShares, representing 63.4666% of the
voting rights in respect of issued share capital of the Company.



                                                                                                    - ends -


END

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SkyePharma PLC By: /s/ ~~Douglas~~John ~~Parkhill~~Murphy Name: ~~Douglas~~John ~~Parkhill~~Murphy Title: Company Secretary

Date: ~~December~~February 2820, ~~2006~~2007

Filing Compare · SKYEPHARMA PLC